Browse Tag

Rani Therapeutics

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

RANI Stock Performance: From Penny Stock to Momentum Rocket Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward in October. It closed on Oct 31 at $2.20, up +51.7% in one day finviz.com on massive volume (~61 million shares vs ~15 million average finviz.com). In fact, over the past month RANI has climbed about 335% finviz.com. Just a few weeks ago in early October it was trading around 50–60 cents; by the first week of November it’s oscillating
3 November 2025
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Stock Performance and Recent Movement Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai (up to $1.085B deal) and a simultaneous $60M financing sent the stock soaring. Intraday Oct 17 it jumped from $0.47 to $2.39 (+248%) ts2.tech. By Oct 31 the stock closed at $2.20, a 51.7% gain on that day alone ts2.tech. This means RANI is up roughly +20% in the past week (from ~$1.82 on Oct 24 to $2.20) and about +330% in October investing.com investing.com.This rally propelled RANI well above
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39 (+248%) ts2.tech stockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21 stockanalysis.com, versus
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

RANI Stock Price Skyrockets on Deal News Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at a $1.64 closing price – a stunning +248% one-day gain investing.com. The prior day, RANI had closed at just $0.47, so the news sparked an almost threefold leap in value. In pre-market trading before the open, the stock had already jumped over +150%, and it continued to rally after the bell ts2.tech ts2.tech. By midday Oct. 17, shares were still
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche reuters.com) to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains (the S&P 500 and Nasdaq Composite were each up only ~0.5% that day investing.com). Deal Details: Under the Chugai
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Key Facts – October 18, 2025 RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price erupted on Friday, Oct. 17, 2025, after the company unveiled its game-changing pharma partnership and a significant financing boost. In pre-market trading, RANI shares jumped over +150%, and the rally continued after the opening bell ts2.tech ts2.tech. The stock — which had closed at just $0.47 the day before — briefly hit about $1.37 intraday (nearly a 3× gain) on extremely heavy volume ts2.tech ts2.tech. By midday, RANI was still trading around $1.30, up ~180% on the day, marking a stunning one-day surge
Go toTop